Everolimus Toxicity in a Kidney Transplant Recipient Treated with Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir for Chronic Hepatitis C

AKIN M., Buldukoglu O. C., ADANIR H., Yalcinkaya T., YILMAZ V. T., YILDIRIM B., ...Daha Fazla

TURKISH JOURNAL OF NEPHROLOGY, cilt.29, sa.1, ss.82-83, 2020 (ESCI) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 29 Sayı: 1
  • Basım Tarihi: 2020
  • Doi Numarası: 10.5152/turkjnephrol.2020.3567
  • Dergi Adı: TURKISH JOURNAL OF NEPHROLOGY
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.82-83
  • Anahtar Kelimeler: Everolimus, toxicity, chronic hepatitis C, ombitasvir/paritaprevir/ritonavir, DRUG-INTERACTIONS
  • Akdeniz Üniversitesi Adresli: Evet

Özet

The incidence of chronic hepatitis C virus (HCV) infection in kidney transplant recipients is 5%-15%, and HCV is an important risk factor for posttransplant kidney issues. Novel interferon-free regimens with direct-acting oral antiviral agents have extremely high response rates in solid organ transplant patients with HCV; however, drug-drug interactions, particularly with immunosuppressive agents, should be considered when deciding the treatment. Here we report a case of severe everolimus toxicity in a kidney transplant recipient receiving ombitasvir/paritaprevir/ritonavir and dasabuvir combination treatment.